The primary purpose of the study will be to describe the tolerability of treatment with the optimal dose of LCZ696 (97.2 mg sacubitril / 102.8 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection fraction (HFrEF) in Canada.